Crusia

Enoxaparin Sodium, the active ingredient in Crusia, is a low molecular weight heparin presented as a 120 mg/0.8 ml solution for subcutaneous or intravenous use. It is used for the prevention and treatment of blood clots in various clinical settings. GNH USA supplies Crusia as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Crusia is indicated for the prevention of deep vein thrombosis (DVT) in surgical patients, the treatment of acute DVT and pulmonary embolism, and anticoagulation during haemodialysis. It is a widely used anticoagulant that helps manage and prevent blood clots in high-risk patients.

Crusia is an anticoagulant used to manage and prevent blood clots in various clinical settings. It is particularly effective in the following conditions:

- Prevention of deep vein thrombosis (DVT) in surgical patients: Reduces the risk of blood clots forming in the legs during and after surgery. - Treatment of acute deep vein thrombosis and pulmonary embolism: Helps dissolve existing blood clots and prevents further clot formation. - Anticoagulation during haemodialysis: Ensures blood remains fluid during dialysis to prevent clotting in the extracorporeal circuit.

Crusia, like other anticoagulants, can cause a range of side effects. Common side effects include:

Common Side Effects: - Injection site reactions: Redness, swelling, or pain at the injection site. - Bleeding: Minor bleeding episodes such as nosebleeds or gum bleeding. - Bruising: Increased tendency to bruise easily. - Nausea: Mild stomach discomfort or nausea.

Serious or Rare Side Effects: - Severe bleeding: Uncontrolled bleeding that can be life-threatening. - Allergic reactions: Severe allergic reactions, including anaphylaxis. - Thrombocytopenia: A decrease in platelet count, which can increase the risk of bleeding. - Osteoporosis: Long-term use may lead to bone thinning and increased fracture risk.

Crusia should be used with caution and under medical supervision. Important precautions include:

- Monitoring: Regular blood tests to monitor clotting times and platelet counts. - Dosage adjustment: Adjusting the dose in patients with renal impairment or other risk factors for bleeding. - Surgery: Avoiding elective surgery while on Crusia to reduce the risk of bleeding. - Pregnancy: Consulting a healthcare provider before use during pregnancy or breastfeeding. - Store below 25°C: Keep in the original pack, protect from moisture and light, and do not freeze.

Crusia can interact with other medications, potentially altering its effectiveness or increasing the risk of side effects. Major interactions include:

Major Interactions (Avoid): - Other anticoagulants: Concurrent use with warfarin or other anticoagulants can increase the risk of bleeding. - Nonsteroidal anti-inflammatory drugs (NSAIDs): Increases the risk of gastrointestinal bleeding. - Antiplatelet drugs: Enhances the risk of bleeding when used together.

Moderate Interactions (Monitor Closely): - Thrombolytics: May increase the risk of bleeding when used with Crusia. - Certain antibiotics: Some antibiotics can alter the effectiveness of Crusia. - Herbal supplements: Some herbs, like ginkgo biloba, can increase the risk of bleeding.